论文部分内容阅读
目的研究米非司酮联合甲氨蝶呤治疗异位妊娠的临床效果及安全性,为临床医生治疗异位妊娠提供可靠依据。方法选择异位妊娠患者138例,随机将其分成对照组和治疗组,每组69例。对照组单独采用甲氨蝶呤注射液治疗,治疗组采用米非司酮联合甲氨蝶呤共同治疗,观察两组患者的治疗效果及安全性。结果治疗后,治疗组患者的盆腔包块直径明显小于对照组,血人绒毛膜促性腺激素(β-HCG)水平明显低于对照组,盆腔包块消失时间、血β-HCG水平恢复正常时间明显短于对照组,疗效、输卵管通畅率均明显高于对照组,差异均有统计学意义(P<0.05);两组患者的不良反应发生率相比,差异未见统计学意义(P>0.05)。结论对异位妊娠患者采用米非司酮联合甲氨蝶呤共同治疗,能有效缩短盆腔包块消失时间、血β-HCG水平恢复正常时间,并且不额外增加不良反应,可用于临床推广应用。
Objective To study the clinical efficacy and safety of mifepristone combined with methotrexate in the treatment of ectopic pregnancy and provide a reliable basis for clinicians to treat ectopic pregnancy. Methods 138 cases of ectopic pregnancy were selected randomly divided into control group and treatment group, 69 cases in each group. The control group was treated with methotrexate alone. The treatment group was treated with mifepristone combined with methotrexate, and the therapeutic effect and safety of the two groups were observed. Results After treatment, the diameter of the pelvic mass in the treatment group was significantly smaller than that in the control group, and the level of serum human chorionic gonadotropin (β-HCG) was significantly lower than that in the control group. The pelvic mass disappeared and the blood β-HCG level returned to normal Significantly shorter than the control group, curative effect and tubal patency rate were significantly higher than the control group, the difference was statistically significant (P <0.05); two groups of patients with adverse reactions compared to the difference was not statistically significant (P> 0.05). Conclusion The combination therapy of mifepristone and methotrexate in patients with ectopic pregnancy can effectively shorten the disappearance time of pelvic mass and return the normal level of blood β-HCG to normal time without additional adverse reactions and can be used for clinical popularization and application.